Auto Draft

GSK plc (NYSE:GSK) is one of the 12 Most Undervalued Stocks to Invest In.

On May 18, 2026, GSK plc (NYSE:GSK) announced that the Japan’s Ministry of Health, Labour and Welfare expanded the eligible population for Arexvy to include adults aged 18 to 49 years at increased risk for RSV disease. GSK said Arexvy had previously been approved in Japan for the prevention of RSV disease in all adults aged 60 years and older, and for adults aged 50-59 AIR for RSV disease. The prescribing information was also updated to explicitly include immuno-compromised patients as an increased risk group.

On May 11, 2026, GSK plc (NYSE:GSK) announced an exclusive strategic collaboration with Sino Biopharmaceutical, through its subsidiary Chia Tai Tianqing Pharmaceutical Group, or CTTQ, to accelerate bepirovirsen in mainland China at launch. Bepirovirsen is under priority regulatory review in China as a potential first-in-class treatment for chronic hepatitis B. Under the agreement, CTTQ will handle importation, distribution, hospital access, and promotional and non-promotional activities in mainland China, while GSK will remain the marketing authorization holder and retain responsibility for regulatory, quality, pharmacovigilance, and global medical strategy. GSK International President Mike Crichton said chronic hepatitis B affects 75 million people in China and is a leading cause of liver cancer in the country.

GSK plc (NYSE:GSK) researches, develops, and manufactures vaccines, specialty medicines, and general medicines to prevent and treat disease internationally.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.